Core Viewpoint - The company has entered into a licensing and collaboration agreement with Windward Bio Group's subsidiary, granting exclusive rights for the development and commercialization of QX027N in specified regions outside of Greater China, with potential payments totaling up to $700 million [1] Group 1: Agreement Details - The agreement was signed on December 19, 2025, between the company and LE2025 Therapeutics AG [1] - The licensed regions exclude mainland China, Taiwan, Hong Kong, and Macau [1] Group 2: Financial Implications - The company or its designated subsidiaries are entitled to receive up to $700 million in total payments, which include an upfront payment, equity from Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in the licensed regions [1] Group 3: Product Information - QX027N is a proprietary long-acting bispecific antibody targeting TSLP and IL-13 developed by the company [1]
荃信生物-B(02509)与Windward Bio附属公司就QX027N的开发及商业化签订许可及合作协议